Dunja Simicic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dunja Simicic has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Georg Oeltzschner
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
18 shared publications - Helge Jörn Zöllner
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
17 shared publications - Christopher W. Davies-Jenkins
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
16 shared publications - Richard Anthony Edward Edden
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
13 shared publications - Aaron T. Gudmundson
The Malone Center for Engineering in Healthcare, Johns Hopkins University, Baltimore, MD, USA
7 shared publications Vivek Yedavalli
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
7 shared publications
Latest Publications
- Open Access
Metabolite Relaxation Times at 3T From Birth to 7 Years
Purpose: With growing interest in pediatric MRS to understand the neurochemistry of brain development, it is essential to establish pediatric-specific metabolite T 1 and T 2 relaxation times for reliable quantification of metabolites. Furthermore, characterization of age-related changes in relaxation times may provide insight into developmental differences in tissue microstructure and cellular composition. Therefore, the goals of this study were two-fold: (1) to estimate metabolite T 1 and T 2 relaxation times in a pediatric cohort; and (2) to assess linear relationships between age and relaxation times. Methods: TI- and TE-series data were acquired from the bilateral thalamus in 20 and 25 participants aged between 0 and 7 years, respectively. Data were processed and modelled in Osprey 2.5.0. Metabolite T 1 and T 2 relaxation times of total N-acetylaspartate at 2.0 ppm (tNAA 2.0 ), total creatine at 3.0 ppm (tCr 3.0 ), total creatine at 3.9 ppm (tCr 3.9 ), total choline (tCho), myo-inositol (mI) and the combined glutamate and glutamine (Glx) were estimated by fitting the modelled signal amplitudes to TI-series inversion recovery signal and TE-series exponential decay equations, respectively. Linear relationships with age were tested for metabolite T 1 and T 2 relaxation times using Spearman correlations. Results: tNAA 2.0 and Glx showed significant changes in T 1 with age. tNAA 2.0 , tCr 3.0 , tCho and mI showed significant decrease in T 2 with age. Conclusion: Several metabolites showed significant changes in relaxation times with age in the thalamus region. Therefore, use of age-specific relaxation correction for pediatric studies using the linear equations provided is encouraged for reliable quantification of metabolites.
Open AccessMetabolite Relaxation Times at 3T From Birth to 7 Years
Purpose: With growing interest in pediatric MRS to understand the neurochemistry of brain development, it is essential to establish pediatric-specific metabolite T 1 and T 2 relaxation times for reliable quantification of metabolites. Furthermore, characterization of age-related changes in relaxation times may provide insight into developmental differences in tissue microstructure and cellular composition. Therefore, the goals of this study were two-fold: (1) to estimate metabolite T 1 and T 2 relaxation times in a pediatric cohort; and (2) to assess linear relationships between age and relaxation times. Methods: TI- and TE-series data were acquired from the bilateral thalamus in 20 and 25 participants aged between 0 and 7 years, respectively. Data were processed and modelled in Osprey 2.5.0. Metabolite T 1 and T 2 relaxation times of total N-acetylaspartate at 2.0 ppm (tNAA 2.0 ), total creatine at 3.0 ppm (tCr 3.0 ), total creatine at 3.9 ppm (tCr 3.9 ), total choline (tCho), myo-inositol (mI) and the combined glutamate and glutamine (Glx) were estimated by fitting the modelled signal amplitudes to TI-series inversion recovery signal and TE-series exponential decay equations, respectively. Linear relationships with age were tested for metabolite T 1 and T 2 relaxation times using Spearman correlations. Results: tNAA 2.0 and Glx showed significant changes in T 1 with age. tNAA 2.0 , tCr 3.0 , tCho and mI showed significant decrease in T 2 with age. Conclusion: Several metabolites showed significant changes in relaxation times with age in the thalamus region. Therefore, use of age-specific relaxation correction for pediatric studies using the linear equations provided is encouraged for reliable quantification of metabolites.
- Open Access
- 11 September 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 215
Differential metabolic and cellular brain regional susceptibility in adult rats with chronic liver disease
- 11 September 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 215
Open AccessDifferential metabolic and cellular brain regional susceptibility in adult rats with chronic liver disease
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Ivosidenib and Vorasidenib Decrease Intratumoral 2-Hydroxyglutarate and Total Choline Levels in Patients with Lower-Grade Glioma: An In Vivo MR Spectroscopy Study
Purpose:Isocitrate dehydrogenase (IDH)-mutant (mIDH) gliomas are slow-growing infiltrating tumors of astrocytic or oligodendroglial origin. Mutated metabolic enzymes IDH1 or IDH2 lead to the production of 2-hydroxyglutarate (2HG) that can be measured with optimized in vivo magnetic resonance spectroscopy (MRS). As the 2HG oncometabolite plays a key role in the molecular pathogenesis of mIDH tumor, direct suppression of 2HG production has proven to be a viable intervention strategy, for example, with the small-molecule inhibitors ivosidenib (mIDH1) and vorasidenib (mIDH1/mIDH2). The aim of this study was to explore whether MRS measurements of 2HG can be used to noninvasively monitor response to treatment with mIDH inhibitors and to relate this response to changes in MRI-assessed tumor volume. Experimental Design:Eighteen patients with diagnosed IDH-mutated glioma were enrolled and received ivosidenib or vorasidenib therapy. MRI/MRS scans with 2HG-optimized single-voxel PRESS were performed before treatment and repeated (follow-up) with a median on-drug follow-up of 4.3 months. Results:In the 14 patients that passed spectroscopy quality control (median follow-up 3.9 months), we observed a substantial and significant decrease in 2HG levels (P < 0.001) regardless of tumor and treatment type (astrocytoma/oligodendroglioma and ivosidenib/vorasidenib), whereas total choline (tCho) and glutamine, metabolites characteristically increased in glioma, also showed a significant decrease (P < 0.01). Volumetric assessment revealed a modest decrease on average, indicating tumor growth arrest. Conclusion:The striking reductions in tumor 2HG and tCho levels early following initiation of targeted therapy using an IDH inhibitor suggest that MRS may provide an important tool for monitoring treatment response of lower-grade gliomas.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Ivosidenib and Vorasidenib Decrease Intratumoral 2-Hydroxyglutarate and Total Choline Levels in Patients with Lower-Grade Glioma: An In Vivo MR Spectroscopy Study
Purpose:Isocitrate dehydrogenase (IDH)-mutant (mIDH) gliomas are slow-growing infiltrating tumors of astrocytic or oligodendroglial origin. Mutated metabolic enzymes IDH1 or IDH2 lead to the production of 2-hydroxyglutarate (2HG) that can be measured with optimized in vivo magnetic resonance spectroscopy (MRS). As the 2HG oncometabolite plays a key role in the molecular pathogenesis of mIDH tumor, direct suppression of 2HG production has proven to be a viable intervention strategy, for example, with the small-molecule inhibitors ivosidenib (mIDH1) and vorasidenib (mIDH1/mIDH2). The aim of this study was to explore whether MRS measurements of 2HG can be used to noninvasively monitor response to treatment with mIDH inhibitors and to relate this response to changes in MRI-assessed tumor volume. Experimental Design:Eighteen patients with diagnosed IDH-mutated glioma were enrolled and received ivosidenib or vorasidenib therapy. MRI/MRS scans with 2HG-optimized single-voxel PRESS were performed before treatment and repeated (follow-up) with a median on-drug follow-up of 4.3 months. Results:In the 14 patients that passed spectroscopy quality control (median follow-up 3.9 months), we observed a substantial and significant decrease in 2HG levels (P < 0.001) regardless of tumor and treatment type (astrocytoma/oligodendroglioma and ivosidenib/vorasidenib), whereas total choline (tCho) and glutamine, metabolites characteristically increased in glioma, also showed a significant decrease (P < 0.01). Volumetric assessment revealed a modest decrease on average, indicating tumor growth arrest. Conclusion:The striking reductions in tumor 2HG and tCho levels early following initiation of targeted therapy using an IDH inhibitor suggest that MRS may provide an important tool for monitoring treatment response of lower-grade gliomas.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary material1 from Ivosidenib and Vorasidenib Decrease Intratumoral 2-Hydroxyglutarate and Total Choline Levels in Patients with Lower-Grade Glioma: An In Vivo MR Spectroscopy Study
Supplementary tables and figures for manuscript “Ivosidenib and Vorasidenib decrease intratumoral 2-hydroxyglutarate and total choline levels in lower-grade glioma: an in vivo MR Spectroscopy study”.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary material1 from Ivosidenib and Vorasidenib Decrease Intratumoral 2-Hydroxyglutarate and Total Choline Levels in Patients with Lower-Grade Glioma: An In Vivo MR Spectroscopy Study
Supplementary tables and figures for manuscript “Ivosidenib and Vorasidenib decrease intratumoral 2-hydroxyglutarate and total choline levels in lower-grade glioma: an in vivo MR Spectroscopy study”.
- Open Access
- 16 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , OF1-OF11
Ivosidenib and Vorasidenib Decrease Intratumoral 2-Hydroxyglutarate and Total Choline Levels in Patients with Lower-Grade Glioma: An In Vivo MR Spectroscopy Study
Purpose: Isocitrate dehydrogenase (IDH)-mutant (mIDH) gliomas are slow-growing infiltrating tumors of astrocytic or oligodendroglial origin. Mutated metabolic enzymes IDH1 or IDH2 lead to the production of 2-hydroxyglutarate (2HG) that can be measured with optimized in vivo magnetic resonance spectroscopy (MRS). As the 2HG oncometabolite plays a key role in the molecular pathogenesis of mIDH tumor, direct suppression of 2HG production has proven to be a viable intervention strategy, for example, with the small-molecule inhibitors ivosidenib (mIDH1) and vorasidenib (mIDH1/mIDH2). The aim of this study was to explore whether MRS measurements of 2HG can be used to noninvasively monitor response to treatment with mIDH inhibitors and to relate this response to changes in MRI-assessed tumor volume. Experimental Design: Eighteen patients with diagnosed IDH-mutated glioma were enrolled and received ivosidenib or vorasidenib therapy. MRI/MRS scans with 2HG-optimized single-voxel PRESS were performed before treatment and repeated (follow-up) with a median on-drug follow-up of 4.3 months. Results: In the 14 patients that passed spectroscopy quality control (median follow-up 3.9 months), we observed a substantial and significant decrease in 2HG levels (P < 0.001) regardless of tumor and treatment type (astrocytoma/oligodendroglioma and ivosidenib/vorasidenib), whereas total choline (tCho) and glutamine, metabolites characteristically increased in glioma, also showed a significant decrease (P < 0.01). Volumetric assessment revealed a modest decrease on average, indicating tumor growth arrest. Conclusion: The striking reductions in tumor 2HG and tCho levels early following initiation of targeted therapy using an IDH inhibitor suggest that MRS may provide an important tool for monitoring treatment response of lower-grade gliomas.
- 16 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (15) , OF1-OF11
Open AccessIvosidenib and Vorasidenib Decrease Intratumoral 2-Hydroxyglutarate and Total Choline Levels in Patients with Lower-Grade Glioma: An In Vivo MR Spectroscopy Study
Purpose: Isocitrate dehydrogenase (IDH)-mutant (mIDH) gliomas are slow-growing infiltrating tumors of astrocytic or oligodendroglial origin. Mutated metabolic enzymes IDH1 or IDH2 lead to the production of 2-hydroxyglutarate (2HG) that can be measured with optimized in vivo magnetic resonance spectroscopy (MRS). As the 2HG oncometabolite plays a key role in the molecular pathogenesis of mIDH tumor, direct suppression of 2HG production has proven to be a viable intervention strategy, for example, with the small-molecule inhibitors ivosidenib (mIDH1) and vorasidenib (mIDH1/mIDH2). The aim of this study was to explore whether MRS measurements of 2HG can be used to noninvasively monitor response to treatment with mIDH inhibitors and to relate this response to changes in MRI-assessed tumor volume. Experimental Design: Eighteen patients with diagnosed IDH-mutated glioma were enrolled and received ivosidenib or vorasidenib therapy. MRI/MRS scans with 2HG-optimized single-voxel PRESS were performed before treatment and repeated (follow-up) with a median on-drug follow-up of 4.3 months. Results: In the 14 patients that passed spectroscopy quality control (median follow-up 3.9 months), we observed a substantial and significant decrease in 2HG levels (P < 0.001) regardless of tumor and treatment type (astrocytoma/oligodendroglioma and ivosidenib/vorasidenib), whereas total choline (tCho) and glutamine, metabolites characteristically increased in glioma, also showed a significant decrease (P < 0.01). Volumetric assessment revealed a modest decrease on average, indicating tumor growth arrest. Conclusion: The striking reductions in tumor 2HG and tCho levels early following initiation of targeted therapy using an IDH inhibitor suggest that MRS may provide an important tool for monitoring treatment response of lower-grade gliomas.
- Open Access
Real-time AI integration for MR to detect artifacts and guide pulse sequence adaptations
This work presents a first-of-its-kind artificial intelligence (AI-)integrated MR pulse sequence that detects out-of-voxel (OOV) artifacts in real-time (within-TR) and responds prospectively by updating the crusher gradient scheme. Per Excitation Real-time Execution & Guided Responses with Integrated Neural-network Evaluation (PEREGRINE), allows for deployment of deep learning models and pulse sequence updates. In this study, PEREGRINE operated a time-domain (TD) and frequency-domain (FD) convolutional autoencoder that detect OOV artifacts. Scans without (AI-off) and with (AI-on) updates were collected from the medial prefrontal cortex of healthy volunteers using a MEGA-edited MRS experiment. The degree of OOV contamination (OOV Score) was quantified per transient based upon the prevalence of OOV signals in the TD and FD data. OOV Scores above a user-defined threshold triggered an update of the crusher gradient scheme, iterating through 48 permutations (6 axis transpositions × 8 polarity flips). Within each 2-second TR, PEREGRINE successfully provided single-transient OOV Scores and updated gradients accordingly. No difference was observed between the OOV Scores from the full (“Full” condition) AI-on and AI-off sessions due to the AI-on scan cycling over better and worse gradient permutations relative to the AI-off scan. However, the AI-on scan had significantly lower OOV Scores than the AI-off scan when selecting the transients where PEREGRINE persisted (“Dwell” condition) on a given gradient permutation. Ultimately, Fit Quality Number (FQN) from linear combination modeling improved significantly for the AI-on compared to the AI-off scan. PEREGRINE enabled an adaptive and AI-integrated sequence allowing for real-time evaluation and response to OOV artifacts, identifying gradient modifications that produced less OOV contamination. Graphical Graphical Abstract Summary: PEREGRINE, Per Excitation Real-time Execution & Guided Responses with Integrated Neural-network Evaluation, allows for pulse sequence updates using on-scanner deployed neural networks. To demonstrate the utility, PEREGRINE was used to operate two neural networks (time/frequency domain), trained to detect out-of-voxel artifacts, during a MEGA-edited MRS experiment in the prefrontal cortex. When artifacts were detected, PEREGRINE updated the crusher gradients within the same TR. Real-time, adaptive, and AI-driven MR will provide a long-awaited solution for combatting artifacts and poor data quality. Graphical Abstract Figure:
Open AccessReal-time AI integration for MR to detect artifacts and guide pulse sequence adaptations
This work presents a first-of-its-kind artificial intelligence (AI-)integrated MR pulse sequence that detects out-of-voxel (OOV) artifacts in real-time (within-TR) and responds prospectively by updating the crusher gradient scheme. Per Excitation Real-time Execution & Guided Responses with Integrated Neural-network Evaluation (PEREGRINE), allows for deployment of deep learning models and pulse sequence updates. In this study, PEREGRINE operated a time-domain (TD) and frequency-domain (FD) convolutional autoencoder that detect OOV artifacts. Scans without (AI-off) and with (AI-on) updates were collected from the medial prefrontal cortex of healthy volunteers using a MEGA-edited MRS experiment. The degree of OOV contamination (OOV Score) was quantified per transient based upon the prevalence of OOV signals in the TD and FD data. OOV Scores above a user-defined threshold triggered an update of the crusher gradient scheme, iterating through 48 permutations (6 axis transpositions × 8 polarity flips). Within each 2-second TR, PEREGRINE successfully provided single-transient OOV Scores and updated gradients accordingly. No difference was observed between the OOV Scores from the full (“Full” condition) AI-on and AI-off sessions due to the AI-on scan cycling over better and worse gradient permutations relative to the AI-off scan. However, the AI-on scan had significantly lower OOV Scores than the AI-off scan when selecting the transients where PEREGRINE persisted (“Dwell” condition) on a given gradient permutation. Ultimately, Fit Quality Number (FQN) from linear combination modeling improved significantly for the AI-on compared to the AI-off scan. PEREGRINE enabled an adaptive and AI-integrated sequence allowing for real-time evaluation and response to OOV artifacts, identifying gradient modifications that produced less OOV contamination. Graphical Graphical Abstract Summary: PEREGRINE, Per Excitation Real-time Execution & Guided Responses with Integrated Neural-network Evaluation, allows for pulse sequence updates using on-scanner deployed neural networks. To demonstrate the utility, PEREGRINE was used to operate two neural networks (time/frequency domain), trained to detect out-of-voxel artifacts, during a MEGA-edited MRS experiment in the prefrontal cortex. When artifacts were detected, PEREGRINE updated the crusher gradients within the same TR. Real-time, adaptive, and AI-driven MR will provide a long-awaited solution for combatting artifacts and poor data quality. Graphical Abstract Figure:
- Open Access
- 14 December 2025
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 95 (4) , 1921-1933
Identifying Out‐of‐Voxel Echoes in Edited MRS With Phase Cycle Inversion
Purpose: To identify the origin of out‐of‐voxel (OOV) signals based on the coherence transfer pathway (CTP) formalism using signal phase conferred by the acquisition phase cycling scheme. Knowing the CTP driving OOV artifacts enables optimization of crusher gradients to improve their suppression. Theory and Methods: A phase cycle systematically changes the phase of RF pulses across the transients of an experiment, encoding phase shifts into the data that can be used to suppress unwanted CTPs. We present a new approach, phase cycle inversion (PCI), which removes the receiver phase originally applied to the stored transients, replacing it with new receiver phases, matching the phase evolutions associated with each unwanted CTP, to identify the OOV signals. We demonstrated the efficacy of PCI using the MEGA‐edited PRESS sequence in simulations, phantom and in vivo experiments at 3T, and for short echo time STEAM at 7T. Based on these findings, the crusher gradient scheme was optimized for a MEGA‐edited PRESS sequence. Results: The simulation results demonstrated that PCI can fully separate signals originating from different CTPs using a complete phase cycling scheme. PCI effectively identified the CTP responsible for OOV signals in phantom experiments and in vivo, though with reduced specificity in vivo due to phase instabilities. Re‐optimization of the gradient scheme based on the identified OOV‐associated CTP to suppress these signals, resulted in cleaner spectra. Conclusion: PCI can be broadly applied across pulse sequences and voxel locations, making it a flexible and generalizable approach for diagnosing the CTP origin of OOV signals.
- 14 December 2025
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 95 (4) , 1921-1933
Open AccessIdentifying Out‐of‐Voxel Echoes in Edited MRS With Phase Cycle Inversion
Purpose: To identify the origin of out‐of‐voxel (OOV) signals based on the coherence transfer pathway (CTP) formalism using signal phase conferred by the acquisition phase cycling scheme. Knowing the CTP driving OOV artifacts enables optimization of crusher gradients to improve their suppression. Theory and Methods: A phase cycle systematically changes the phase of RF pulses across the transients of an experiment, encoding phase shifts into the data that can be used to suppress unwanted CTPs. We present a new approach, phase cycle inversion (PCI), which removes the receiver phase originally applied to the stored transients, replacing it with new receiver phases, matching the phase evolutions associated with each unwanted CTP, to identify the OOV signals. We demonstrated the efficacy of PCI using the MEGA‐edited PRESS sequence in simulations, phantom and in vivo experiments at 3T, and for short echo time STEAM at 7T. Based on these findings, the crusher gradient scheme was optimized for a MEGA‐edited PRESS sequence. Results: The simulation results demonstrated that PCI can fully separate signals originating from different CTPs using a complete phase cycling scheme. PCI effectively identified the CTP responsible for OOV signals in phantom experiments and in vivo, though with reduced specificity in vivo due to phase instabilities. Re‐optimization of the gradient scheme based on the identified OOV‐associated CTP to suppress these signals, resulted in cleaner spectra. Conclusion: PCI can be broadly applied across pulse sequences and voxel locations, making it a flexible and generalizable approach for diagnosing the CTP origin of OOV signals.
- Open Access
- 19 November 2025
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (1) , e70182
Gradient Scheme Optimization for PRESS‐Localized Edited MRS Using Weighted Pathway Suppression
This study aimed to design and implement an optimized gradient scheme for PRESS‐localized edited magnetic resonance spectroscopy (MRS) to enhance suppression of out‐of‐voxel (OOV) artifacts. These artifacts, which originate from insufficient crushing of unwanted coherence transfer pathways (CTPs), are particularly challenging in editing schemes for metabolites like gamma‐aminobutyric acid and glutathione. To address this, a volume‐based likelihood model was developed to guide gradient scheme optimization, prioritizing suppression of CTPs based on likelihood. The volume‐based likelihood model for CTP weighting was integrated into a Dephasing optimization through coherence order pathway selection (DOTCOPS) gradient optimization. Using a genetic algorithm with a weighted dual‐penalty cost function, gradient schemes were optimized to maximize pathway‐specific suppression. Hardware and sequence constraints, maximum gradient amplitudes and delay durations respectively, informed the optimization. Validation of the optimized scheme was performed with simulations by calculating the k‐space crushing efficiency analytically with k‐space trajectory and in vivo using an edited MRS sequence in three brain regions (posterior cingulate cortex PCC, thalamus, and medial prefrontal cortex [mPFC]), with particular focus on OOV artifact reduction and spectral quality improvements. A three‐way Analysis of Variance was used to assess the significance level of OOV artifact reduction. The optimized gradient scheme demonstrated improved k‐space crushing efficiency (by an average of 197%). OOV artifacts were reduced in all brain regions, particularly in highly OOV‐susceptible regions (thalamus and mPFC). Improvements were most notable around 4.3 ppm with significant OOV artifact amplitude reductions ( p < 0.001). By using a volume‐based likelihood model for CTP prioritization, the optimized DOTCOPS scheme ensures robust and region‐agnostic performance in reducing OOV artifacts.
- 19 November 2025
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (1) , e70182
Open AccessGradient Scheme Optimization for PRESS‐Localized Edited MRS Using Weighted Pathway Suppression
This study aimed to design and implement an optimized gradient scheme for PRESS‐localized edited magnetic resonance spectroscopy (MRS) to enhance suppression of out‐of‐voxel (OOV) artifacts. These artifacts, which originate from insufficient crushing of unwanted coherence transfer pathways (CTPs), are particularly challenging in editing schemes for metabolites like gamma‐aminobutyric acid and glutathione. To address this, a volume‐based likelihood model was developed to guide gradient scheme optimization, prioritizing suppression of CTPs based on likelihood. The volume‐based likelihood model for CTP weighting was integrated into a Dephasing optimization through coherence order pathway selection (DOTCOPS) gradient optimization. Using a genetic algorithm with a weighted dual‐penalty cost function, gradient schemes were optimized to maximize pathway‐specific suppression. Hardware and sequence constraints, maximum gradient amplitudes and delay durations respectively, informed the optimization. Validation of the optimized scheme was performed with simulations by calculating the k‐space crushing efficiency analytically with k‐space trajectory and in vivo using an edited MRS sequence in three brain regions (posterior cingulate cortex PCC, thalamus, and medial prefrontal cortex [mPFC]), with particular focus on OOV artifact reduction and spectral quality improvements. A three‐way Analysis of Variance was used to assess the significance level of OOV artifact reduction. The optimized gradient scheme demonstrated improved k‐space crushing efficiency (by an average of 197%). OOV artifacts were reduced in all brain regions, particularly in highly OOV‐susceptible regions (thalamus and mPFC). Improvements were most notable around 4.3 ppm with significant OOV artifact amplitude reductions ( p < 0.001). By using a volume‐based likelihood model for CTP prioritization, the optimized DOTCOPS scheme ensures robust and region‐agnostic performance in reducing OOV artifacts.
- Open Access
- 16 August 2025
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 95 (1) , 20-37
A data‐driven algorithm to determine 1 H ‐ MRS basis set composition
Purpose: Metabolite amplitude estimates derived from linear combination modeling of MR spectra depend on the precise list of constituent metabolite basis functions used (the “basis set”). The absence of clear consensus on the “ideal” composition or objective criteria to determine the suitability of a particular basis set contributes to the poor reproducibility of MRS. In this proof‐of‐concept study, we demonstrate a novel, data‐driven approach for deciding the basis‐set composition using Akaike information criteria (AIC). Methods: We have developed an algorithm that iteratively adds metabolites to the basis set using iterative modeling, informed by AIC scores. We investigated two quantitative “stopping conditions,” referred to as max‐AIC and zero‐amplitude, and whether to optimize the selection of basis set on a per‐spectrum basis or at the group level. The algorithm was tested using two groups of synthetic in vivo‐like spectra representing healthy brain and tumor spectra, respectively, and the derived basis sets (and metabolite amplitude estimates) were compared to the ground truth. Results: All derived basis sets correctly identified high‐concentration metabolites and provided reasonable fits of the spectra. At the single‐spectrum level, the two stopping conditions derived the underlying basis set with 84% to 88% accuracy. When optimizing across a group, basis set determination accuracy improved to 89% to 92%. Conclusion: Data‐driven determination of the basis set composition is feasible. With refinement, this approach could provide a valuable data‐driven way to derive or refine basis sets, reducing the operator bias of MRS analyses, enhancing the objectivity of quantitative analyses, and increasing the clinical viability of MRS.
- 16 August 2025
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 95 (1) , 20-37
Open AccessA data‐driven algorithm to determine 1 H ‐ MRS basis set composition
Purpose: Metabolite amplitude estimates derived from linear combination modeling of MR spectra depend on the precise list of constituent metabolite basis functions used (the “basis set”). The absence of clear consensus on the “ideal” composition or objective criteria to determine the suitability of a particular basis set contributes to the poor reproducibility of MRS. In this proof‐of‐concept study, we demonstrate a novel, data‐driven approach for deciding the basis‐set composition using Akaike information criteria (AIC). Methods: We have developed an algorithm that iteratively adds metabolites to the basis set using iterative modeling, informed by AIC scores. We investigated two quantitative “stopping conditions,” referred to as max‐AIC and zero‐amplitude, and whether to optimize the selection of basis set on a per‐spectrum basis or at the group level. The algorithm was tested using two groups of synthetic in vivo‐like spectra representing healthy brain and tumor spectra, respectively, and the derived basis sets (and metabolite amplitude estimates) were compared to the ground truth. Results: All derived basis sets correctly identified high‐concentration metabolites and provided reasonable fits of the spectra. At the single‐spectrum level, the two stopping conditions derived the underlying basis set with 84% to 88% accuracy. When optimizing across a group, basis set determination accuracy improved to 89% to 92%. Conclusion: Data‐driven determination of the basis set composition is feasible. With refinement, this approach could provide a valuable data‐driven way to derive or refine basis sets, reducing the operator bias of MRS analyses, enhancing the objectivity of quantitative analyses, and increasing the clinical viability of MRS.
- 2 May 2025
- Published by Wiley in NMR in Biomedicine
- Vol. 38 (6) , e70039
Reproducibility Made Easy: A Tool for Methodological Transparency and Efficient Standardized Reporting Based on the Proposed MRSinMRS Consensus
Recent expert consensus publications have highlighted the issue of poor reproducibility in magnetic resonance spectroscopy (MRS) studies, mainly due to the lack of standardized reporting criteria, which affects their clinical applicability. To combat this, guidelines for minimum reporting standards (MRSinMRS) were introduced to aid journal editors and reviewers in ensuring the comprehensive documentation of essential MRS study parameters. Despite these efforts, the implementation of MRSinMRS standards has been slow, attributed to the diverse nomenclature used by different vendors, the variety of raw MRS data formats, and the absence of appropriate software tools for identifying and reporting necessary parameters. To overcome this obstacle, we have developed the REproducibility Made Easy (REMY) standalone toolbox. REMY software supports a range of MRS data formats from major vendors like GE (.7), Siemens (.ima, .rda, .dcm), Philips (.spar/.sdat), and Bruker (.method), and MRS‐NIfTI (.nii/nii.gz/.json) files facilitating easy data import and export through a user‐friendly interface. REMY employs external libraries such as spec2nii and pymapVBVD to accurately read and process these diverse data formats, translating complex header information into a comprehensive structure that adheres to consensus reporting standards, thereby ensuring compatibility and ease of use for researchers in generating reproducible MRS research outputs. Users can select and import datasets, choose the appropriate vendor and data format, and then generate an MRSinMRS table, log file, and methodological documents in both Latex and PDF formats by just clicking one button. No coding knowledge is required, making the tool accessible to a wider range of users, including researchers and clinicians without programming expertise. This eliminates technical challenges related to data formatting and reporting. REMY effectively populated key sections of the MRSinMRS table with data from all supported file types. Accurate generation of hardware parameters including field strength, manufacturer, and scanner software version were demonstrated. However, it could not input data for RF coil and additional hardware information due to their absence in the files. For the acquisition section, REMY accurately read and populated fields for the pulse sequence name, nominal voxel size, repetition time (TR), echo time (TE), number of acquisitions/excitations/shots, spectral width (Hz), and number of spectral points, significantly contributing to the completion of the “Acquisition” fields of the table. Furthermore, REMY generates a boilerplate methods text section for manuscripts. The use of REMY will facilitate more widespread adoption of the MRSinMRS checklist within the MRS community, making it easier to write and report acquisition parameters effectively.
- 2 May 2025
- Published by Wiley in NMR in Biomedicine
- Vol. 38 (6) , e70039
Reproducibility Made Easy: A Tool for Methodological Transparency and Efficient Standardized Reporting Based on the Proposed MRSinMRS Consensus
Recent expert consensus publications have highlighted the issue of poor reproducibility in magnetic resonance spectroscopy (MRS) studies, mainly due to the lack of standardized reporting criteria, which affects their clinical applicability. To combat this, guidelines for minimum reporting standards (MRSinMRS) were introduced to aid journal editors and reviewers in ensuring the comprehensive documentation of essential MRS study parameters. Despite these efforts, the implementation of MRSinMRS standards has been slow, attributed to the diverse nomenclature used by different vendors, the variety of raw MRS data formats, and the absence of appropriate software tools for identifying and reporting necessary parameters. To overcome this obstacle, we have developed the REproducibility Made Easy (REMY) standalone toolbox. REMY software supports a range of MRS data formats from major vendors like GE (.7), Siemens (.ima, .rda, .dcm), Philips (.spar/.sdat), and Bruker (.method), and MRS‐NIfTI (.nii/nii.gz/.json) files facilitating easy data import and export through a user‐friendly interface. REMY employs external libraries such as spec2nii and pymapVBVD to accurately read and process these diverse data formats, translating complex header information into a comprehensive structure that adheres to consensus reporting standards, thereby ensuring compatibility and ease of use for researchers in generating reproducible MRS research outputs. Users can select and import datasets, choose the appropriate vendor and data format, and then generate an MRSinMRS table, log file, and methodological documents in both Latex and PDF formats by just clicking one button. No coding knowledge is required, making the tool accessible to a wider range of users, including researchers and clinicians without programming expertise. This eliminates technical challenges related to data formatting and reporting. REMY effectively populated key sections of the MRSinMRS table with data from all supported file types. Accurate generation of hardware parameters including field strength, manufacturer, and scanner software version were demonstrated. However, it could not input data for RF coil and additional hardware information due to their absence in the files. For the acquisition section, REMY accurately read and populated fields for the pulse sequence name, nominal voxel size, repetition time (TR), echo time (TE), number of acquisitions/excitations/shots, spectral width (Hz), and number of spectral points, significantly contributing to the completion of the “Acquisition” fields of the table. Furthermore, REMY generates a boilerplate methods text section for manuscripts. The use of REMY will facilitate more widespread adoption of the MRSinMRS checklist within the MRS community, making it easier to write and report acquisition parameters effectively.